Pfizer announces positive CHMP opinion for RSV vaccine candidate

Pfizer announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorization for Pfizer’s respiratory syncytial virus, or RSV, vaccine candidate, PF-06928316 or RSVpreF, for both older adults and maternal immunization to help protect infants. “The CHMP’s positive opinion will now be reviewed by the European Commission. The EC will take the CHMP’s recommendation under advisement to decide whether to approve RSVpreF, whose trade name in the European Union will be ABRYSVO. The EC’s final decision is expected in the coming weeks and will apply to all 27 EU member states plus Iceland, Liechtenstein, and Norway,” the company said.